Synergy CHC Corp. Reports Third Quarter 2025 Financial Results and its Eleventh Consecutive Quarter of Profitability
Rhea-AI Summary
Synergy CHC Corp (NASDAQ: SNYR) reported third quarter 2025 results on Nov 13, 2025, marking its 11th consecutive profitable quarter. Revenue was $8.0M (up 12.4% YoY) and gross margin expanded to 70.9% (vs. 67.2%), driven by a favorable product mix. Income from operations rose to $1.28M, while net income declined to $0.125M from $0.784M a year earlier. Adjusted EBITDA was $1.52M (up 13.4% YoY).
Balance sheet moves included a completed $4.4M public offering in August, a reduction of liabilities by $3.3M, cash of ~$1.0M, and a working capital surplus of $16.68M as of Sept 30, 2025.
Positive
- Revenue +12.4% YoY to $8.0M
- Gross margin expanded by 370 bps to 70.9%
- Adjusted EBITDA +13.4% to $1.52M
- Completed $4.4M public offering on Aug 27, 2025
- Working capital improved to a $16.68M surplus as of Sep 30, 2025
- Outstanding liabilities reduced by $3.3M during the quarter
Negative
- Net income declined from $0.784M to $0.125M
- Operating expenses rose 17.7% to $4.4M
- Cash used in operating activities increased to $3.21M for YTD nine months
- Cash on hand only $1.0M as of Sep 30, 2025
News Market Reaction 4 Alerts
On the day this news was published, SNYR declined 6.37%, reflecting a notable negative market reaction. Argus tracked a trough of -6.2% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $24M at that time.
Data tracked by StockTitan Argus on the day of publication.
WESTBROOK, Maine, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a leading consumer health and wellness company, is announcing its financial results for the three months ended September 30, 2025.
“We are pleased to report our 11th quarter of profitability and double-digit revenue growth, accompanied by over 300 basis points of gross margin expansion,” said Jack Ross, CEO of Synergy CHC Corp. “We made meaningful progress across our strategic priorities by expanding retail authorizations and distribution partnerships for our FOCUSfactor functional beverages and shots. Key partnerships with leading retailers, including Kroger and Wakefern, are strengthening our reach across North America. Additionally, we completed a
Third Quarter 2025 Financial Summary vs. Same Year-Ago Period
- Revenue of
$8.0 million vs.$7.1 million . - Gross margin of
70.9% vs.67.2% . - Income from operations of
$1.28 million vs.$1.05 million . - Net income of
$125.3 thousand vs.$783.6 thousand . - Earnings per share of
$0.01 vs.$0.11 . - EBITDA, a non-GAAP financial measure, was
$1.31 million vs.$1.33 million . - Adjusted EBITDA, a non-GAAP financial measure, was
$1.52 million vs.$1.34 million . - Adjusted EBITDA per share, a non-GAAP financial measure, was
$0.15 vs.$0.18 .
Recent Business Highlights
- Synergy recently announced multiple new retail and distribution wins for its FOCUSfactor supplements and beverages, including placements with Kroger and Wakefern, along with regional partnerships with EG America, AlaBev and Atlantic Importing. These agreements expand FOCUSfactor’s U.S. footprint across grocery, pharmacy and convenience channels.
- On August 27, 2025, Synergy announced the completion of its
$4.4 million underwritten public offering of common stock, providing additional working capital to support continued growth initiatives. - On September 22, 2025, Synergy appointed former Costco executive Teresa Thompson to the Board of Directors, strengthening the Company’s retail and consumer health expertise.
- During the third quarter, the Company reduced outstanding liabilities by
$3.3 million . - Subsequent to quarter end, Synergy announced that FOCUSfactor was named the #1 Pharmacist Recommended OTC Memory Supplement for 2025-2026 by Pharmacy Times, underscoring the brand’s category leadership and continued consumer and professional trust.
Third Quarter 2025 Financial Results
Revenue in the third quarter of 2025 was
Gross margin in the third quarter of 2025 was
Operating expenses in the third quarter of 2025 were
Income from operations for the third quarter of 2025 was
Net income in the third quarter of 2025 was
Earnings per share in the third quarter of 2025 was
EBITDA (a non-GAAP financial measure) in the third quarter of 2025 was
Adjusted EBITDA (a non-GAAP financial measure) in the third quarter of 2025 was
Adjusted EBITDA per share (a non-GAAP financial measure) in the third quarter was
Balance Sheet and Cash Flow
As of September 30, 2025, Synergy had approximately
As of September 30, 2025, Synergy had a working capital surplus of
As of September 30, 2025, Synergy had
Cash used in operating activities for the nine months ended September 30, 2025 was
Non-GAAP Financial Measure Reconciliation: EBITDA and Adjusted EBITDA
To assist financial statement users in an assessment of our historical performance, the Company discloses non-GAAP financial measures in press releases and on investor conference calls and related events, as the Company believes that the non-GAAP information enhances investors' overall understanding of our financial performance, and should be read in addition to, rather than instead of, the financial statements prepared in accordance with GAAP.
Management believes EBITDA and Adjusted EBITDA provide useful information to investors by excluding certain items that may not be indicative of the Company’s core operating results and that can vary significantly between periods. EBITDA is defined as net income plus interest expense, income tax expense, depreciation and amortization. Adjusted EBITDA is calculated as EBITDA plus or minus foreign exchange gains or losses and non-cash expenses.
The following table reconciles net income to EBITDA and Adjusted EBITDA (in millions of US dollars):
| 3 Months ended September 30 | ||||||
| 2025 | 2024 | |||||
| Net income for the period | ||||||
| Adjusted for: | ||||||
| Interest expense, net | 1.16 | 0.71 | ||||
| Amortization of intangible assets | 0.03 | 0.03 | ||||
| Tax benefit | (0.01) | (0.19) | ||||
| EBITDA | ||||||
| Foreign currency adjustment | 0.02 | 0.01 | ||||
| Stock based compensation | 0.19 | - | ||||
| Adjusted EBITDA | ||||||
Conference Call
In conjunction with this announcement, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT on November 13, 2025, with the Company’s Chief Executive Officer, Jack Ross, and the Company’s Chief Financial Officer, Jaime Fickett. A live webcast of the call will be available on the Investor Relations section of Synergy’s website. To access the call by phone, please register here and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time. A replay of the webcast will also be available for a limited time on the Company’s website.
About Synergy CHC Corp.
Synergy CHC Corp. develops and markets consumer health and wellness products, led by its flagship brands FOCUSfactor® and Flat Tummy®. FOCUSfactor®, a clinically studied brain health supplement and functional beverage line with a 25-year legacy, enjoys established distribution in the U.S., Canada, and the U.K. through major retailers including Costco, Walmart, Amazon, BJ's, and Walgreens, among others. The brand continues to accelerate growth, penetrating new markets both domestically and internationally, with recent retail wins across mass, grocery, pharmacy, convenience, and wholesale channels poised to drive meaningful gains in late 2025. Flat Tummy® complements Synergy's portfolio as a lifestyle brand focused on women's wellness and weight management.
Forward Looking Statements
Certain statements contained in this press release constitute "forward-looking statements," including statements regarding brand expansion and growth initiatives. These forward-looking statements represent Synergy's expectations or beliefs concerning future events, and it is possible that the results described in this press release will not be achieved. These forward-looking statements are subject to risks, uncertainties and other factors, which are set forth in Synergy's registration statement on Form S-1, as amended, many of which are outside of Synergy's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements.
Any forward-looking statement speaks only as of the date on which it is made, and, except as required by law, Synergy does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for Synergy to predict all such factors. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements in Synergy’s filings with the SEC. The risk factors and other factors noted in Synergy's filings could cause its actual results to differ materially from those contained in any forward-looking statement.
Investor Relations
Gateway Group
Cody Slach, Greg Robles
949.574.3860
SNYR@gateway-grp.com
| Synergy CHC Corp. Condensed Consolidated Balance Sheets | ||||||||
| September 30, 2025 | December 31, 2024 | |||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Current Assets | ||||||||
| Cash and cash equivalents | $ | 1,006,489 | $ | 687,920 | ||||
| Restricted cash | 100,000 | 100,000 | ||||||
| Accounts receivable, net | 6,812,649 | 5,321,037 | ||||||
| Other receivables | 2,182,755 | 1,999,637 | ||||||
| Loan receivable (related party) | 4,407,449 | 4,375,059 | ||||||
| Prepaid expenses (including related party amount of | 3,852,311 | 1,859,563 | ||||||
| Inventory, net | 2,145,966 | 1,716,552 | ||||||
| Total Current Assets | 20,507,619 | 16,059,768 | ||||||
| Intangible assets, net | 183,333 | 283,333 | ||||||
| Total Assets | $ | 20,690,952 | $ | 16,343,101 | ||||
| Liabilities and Stockholders’ Deficit | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable and accrued liabilities (including payable to shareholder of | $ | 3,573,505 | $ | 5,191,868 | ||||
| Income taxes payable | 254,763 | 242,977 | ||||||
| Contract liabilities | 1,854 | 24,252 | ||||||
| Short term loans payable, net of debt discount | - | 7,725,272 | ||||||
| Current portion of long-term notes payable, net of debt discount and debt issuance cost, shareholder | - | 4,000,000 | ||||||
| Total Current Liabilities | 3,830,122 | 17,184,369 | ||||||
| Long-term Liabilities: | ||||||||
| Notes payable, net of debt discount, shareholder | - | 8,333,053 | ||||||
| Notes payable, net of debt discount | 25,113,177 | 7,457,022 | ||||||
| Total long-term liabilities | 25,113,177 | 15,790,075 | ||||||
| Total Liabilities | 28,943,299 | 32,974,444 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ Deficit: | ||||||||
| Common stock, | 114 | 87 | ||||||
| Additional paid in capital | 33,535,939 | 27,643,660 | ||||||
| Accumulated other comprehensive loss | (35,915 | ) | (47,777 | ) | ||||
| Accumulated deficit | (41,624,985 | ) | (44,099,813 | ) | ||||
| Less: Treasury stock (180,073 shares) at cost | (127,500 | ) | (127,500 | ) | ||||
| Total stockholders’ deficit | (8,252,347 | ) | (16,631,343 | ) | ||||
| Total Liabilities and Stockholders’ Deficit | $ | 20,690,952 | $ | 16,343,101 | ||||
| Synergy CHC Corp. Unaudited Condensed Consolidated Statements of Income and Comprehensive Income | ||||||||||||||||
| For the three months ended | For the nine months ended | |||||||||||||||
| September 30, 2025 | September 30, 2024 | September 30, 2025 | September 30, 2024 | |||||||||||||
| Revenue | ||||||||||||||||
| Product Sales | $ | 8,010,112 | $ | 7,126,333 | $ | 21,415,642 | $ | 24,563,039 | ||||||||
| License Revenue | - | - | 2,900,000 | - | ||||||||||||
| Total Revenue | 8,010,112 | 7,126,333 | 24,315,642 | 24,563,039 | ||||||||||||
| Cost of sales | 2,329,296 | 2,335,901 | 6,232,201 | 7,421,930 | ||||||||||||
| Gross profit | 5,680,816 | 4,790,432 | 18,083,441 | 17,141,106 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Selling and marketing | 2,729,767 | 2,509,440 | 8,668,249 | 9,149,303 | ||||||||||||
| General and administrative | 1,637,706 | 1,196,784 | 4,463,745 | 3,449,007 | ||||||||||||
| Depreciation and amortization | 33,333 | 33,333 | 100,000 | 100,000 | ||||||||||||
| Total operating expenses | 4,400,806 | 3,739,557 | 13,231,994 | 12,698,310 | ||||||||||||
| Income from operations | 1,280,010 | 1,050,875 | 4,851,447 | 4,442,796 | ||||||||||||
| Other (income) expenses | ||||||||||||||||
| Other income | (252,405 | ) | (252,405 | ) | ||||||||||||
| Interest income | ||||||||||||||||
| Interest expense, net | 1,164,017 | 704,707 | 4,352,840 | 2,559,454 | ||||||||||||
| Gain on settlement of notes payable | - | (2,154,522 | ) | - | ||||||||||||
| Remeasurement loss on translation of foreign subsidiary | 1,773 | 7,279 | 10,762 | 2,166 | ||||||||||||
| Total other (income) expenses | 1,165,790 | 459,581 | 2,209,080 | 2,309,215 | ||||||||||||
| Net income before income taxes | 114,220 | 591,294 | 2,642,367 | 2,133,581 | ||||||||||||
| Income tax benefit (expense) | 11,107 | 192,299 | (167,540 | ) | (114,272 | ) | ||||||||||
| Net income after tax | $ | 125,327 | $ | 783,593 | $ | 2,474,827 | $ | 2,019,309 | ||||||||
| Net income per share – basic | $ | 0.01 | $ | 0.11 | $ | 0.27 | $ | 0.27 | ||||||||
| Net income per share – diluted | $ | 0.01 | $ | 0.11 | $ | 0.27 | $ | 0.27 | ||||||||
| Weighted average common shares outstanding | ||||||||||||||||
| Basic | 10,110,114 | 7,373,745 | 9,204,136 | 7,373,745 | ||||||||||||
| Diluted | 10,111,134 | 7,373,745 | 9,204,136 | 7,373,745 | ||||||||||||
| Comprehensive income: | ||||||||||||||||
| Net income | 125,327 | 783,593 | 2,474,827 | 2,019,309 | ||||||||||||
| Foreign currency translation adjustment | (26,077 | ) | (79,025 | ) | 11,862 | 108,348 | ||||||||||
| Comprehensive income | $ | 99,250 | $ | 704,568 | $ | 2,486,689 | $ | 2,127,657 | ||||||||
| Synergy CHC Corp. Unaudited Condensed Consolidated Statements of Cash Flows | ||||||||
| For the nine months ended | For the nine months ended | |||||||
| September 30, 2025 | September 30, 2024 | |||||||
| Cash Flows from Operating Activities | ||||||||
| Net income | $ | 2,474,827 | $ | 2,019,309 | ||||
| Adjustments to reconcile net income to net cash used in operating activities: | ||||||||
| Amortization of debt discount and debt issuance cost | 1,128,795 | 47,519 | ||||||
| Depreciation and amortization | 100,000 | 100,000 | ||||||
| Stock based compensation | 19,941 | 9,224 | ||||||
| Stock issued for modification of notes payable | 847,062 | - | ||||||
| Stock issued for services | 127,200 | - | ||||||
| Foreign currency transaction loss | 5,655 | 23,777 | ||||||
| Remeasurement loss on translation of foreign subsidiary | 10,763 | 2,166 | ||||||
| Non cash implied interest | - | 4,799 | ||||||
| Gain on settlement of debt | (2,154,522 | ) | - | |||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (1,491,612 | ) | (1,965,936 | ) | ||||
| Other receivables | (183,118 | ) | - | |||||
| Loan receivable, related party | (32,390 | ) | 21,269 | |||||
| Inventory | (429,414 | ) | 1,815,725 | |||||
| Prepaid expenses | (1,255,502 | ) | (205,975 | ) | ||||
| Prepaid expense, related party | (737,246 | ) | (396,683 | ) | ||||
| Income taxes payable | 11,786 | 68,607 | ||||||
| Contract liabilities | (22,398 | ) | (12,102 | ) | ||||
| Accounts payable and accrued liabilities | (2,009,905 | ) | (3,011,384 | ) | ||||
| Accounts payable, shareholder | 380,929 | 102,206 | ||||||
| Net cash used in operating activities | (3,209,149 | ) | (1,377,479 | ) | ||||
| Cash Flows from Investing Activities | - | - | ||||||
| Cash Flows from Financing Activities | ||||||||
| Proceeds from issuing common stock | 3,880,462 | - | ||||||
| Advances from related party | 135,000 | 3,395,587 | ||||||
| Repayment of advances from related party | (135,000 | ) | (157,425 | ) | ||||
| Proceeds from notes payable | 18,996,250 | 600,000 | ||||||
| Payment of loan financing fees | (2,010,953 | ) | - | |||||
| Repayment of notes payable, shareholder | (10,000,000 | ) | (84,500 | ) | ||||
| Repayment of notes payable | (7, 349,903 | ) | (2,857,690 | ) | ||||
| Net cash provided by financing activities | 3,515,856 | 895,972 | ||||||
| Effect of exchange rate on cash, cash equivalents and restricted cash | 11,862 | 108,348 | ||||||
| Net increase (decrease) in cash, cash equivalents and restricted cash | 318,569 | (373,159 | ) | |||||
| Cash and restricted cash, beginning of year | 787,920 | 732,534 | ||||||
| Cash and restricted cash, end of period | $ | 1,106,489 | $ | 359,375 | ||||
| Supplemental Disclosure of Cash Flow Information: | ||||||||
| Cash paid during the period for: | ||||||||
| Interest | $ | 1,824,446 | $ | 2,432,653 | ||||
| Income taxes | $ | - | $ | 45,664 | ||||
| Supplemental Disclosure of Noncash Investing and Financing Activities: | ||||||||
| Accounts payable converted to loan payable upon settlement | $ | - | $ | 3,770,824 | ||||
| Reduction of short term related party note payable by reduction of prepaid balance | $ | - | $ | 328,003 | ||||
| Issuance of common stock for loan financing | $ | 117,648 | $ | - | ||||
| Issuance of pre-funded warrants for settlement of shareholder notes payable | $ | 899,993 | $ | - | ||||
| Exercise of pre-funded warrants | $ | 4 | $ | - | ||||
| Loan fees payable to lender | $ | 375,000 | $ | - | ||||
FAQ
What were Synergy CHC (SNYR) third quarter 2025 revenue and gross margin?
How did Synergy CHC (SNYR) Adjusted EBITDA change in Q3 2025?
What capital raise did Synergy CHC (SNYR) complete in 2025 and when?
Why did Synergy CHC (SNYR) net income fall in Q3 2025 despite revenue growth?
What balance sheet improvements did Synergy CHC (SNYR) report as of Sept 30, 2025?
Which retail partnerships did Synergy CHC (SNYR) announce in Q3 2025 for FOCUSfactor?
